Keywords: Glenmark, Sanofi, GBR 500, Crohn's disease, Inflammatory conditions

Glenmark sells rights to Crohn’s drug to Sanofi for up to $613 million

Article | 17 May 2011

Print This

In a second licensing deal between the companies, Indian drugmaker Glenmark Pharmaceuticals, through its US unit, has entered into an ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in